Cerebral cavernous malformations (CCMs), or cavernomas, are rounded or oval lesions in the CNS consisting of dilated vascular channels with single layer of endothelium, lacking muscular and elastic layers, without normal intervening brain parenchyma. Developmental venous anomalies may coexist with CCMs in up to 30% of cases, and along with capillary telangiectasias and arteriovenous malformations, comprise 4 types of vascular malformations found in CNS.
Cavernomas have certain clinical and imaging characteristics. They are found in patients in the second through fifth decade of life, with an increasing number of asymptomatic lesions found due to the increasing availability of brain MRI. Symptomatic, affected patients may present with seizures, intracranial hemorrhage, or focal neurologic deficits, but up to 50% remain asymptomatic over a lifetime. 1 Most CCMs are located supratentorially, but 20% occur in the posterior fossa. Rarely, CCMs can occur in the spinal cord or involve cranial nerves or the retina, often coexisting with multiple brain CCMs. When seen on CT, CCMs can be mistaken for (sub)acute intracerebral hemorrhage (ICH) or secondary brain lesions. On MRI, CCMs have a classic "popcorn" appearance on T2-weighted imaging, with surrounding hypointensity representing a hemosiderin rim. CCMs always carry hemosiderin easily detected on gradient echo (T2*) or susceptibility-weighted images. Rarely, CCMs have atypical radiographic features such as surrounding vasogenic edema, mass effect, and fluid-fluid level. 2 The presence of multiple CCMs in an individual or 2 or more affected family members of an individual with a solitary CCM suggests an autosomal dominant familial form of CCM. To date, the 3 characterized autosomal dominant forms correspond to mutations in KRIT1 (CCM1), MGC4607 (CCM2), and PDCD10 (CCM3). Current treatment options for CCMs include conservative management, microsurgical excision, or stereotactic radiosurgery. Untreated lesions seem to have a low spontaneous bleeding risk, especially cavernomas without prior symptomatic hemorrhage. 3 In this issue of Neurology ® , Moultrie et al. 4 present results on outcomes after surgical or conservative management of CCMs. This prospectively designed, population-based study identified Scottish residents with definite CCM diagnosis based on pathologic examination after excision or brain MRI. Patients were classified as managed conservatively if they did not receive surgical or radiosurgical CCM treatment within 5 years after initial presentation, or treated if they had undergone microsurgical excision or stereotactic radiosurgery of the CCM over this same time period. The patients' physicians made all treatment decisions. Of the 134 patients studied, 25 underwent microsurgery for excision of CCM a median of 10 months after initial presentation. For the primary analysis, the investigators defined poor outcome as at least 2 successive ratings of Oxford Handicap Scale (OHS) score 2-6 (OHS derivative of modified Rankin Scale scoring system). The secondary analyses included a composite of symptomatic ICH or new focal neurologic deficit (FND). The group undergoing CCM excision progressed to a poor outcome twice as frequently as the conservatively managed group (adjusted hazard ratio 2.2, 95% confidence interval 1.1-4.2). Similarly, the patients who underwent CCM excision endured a higher risk of experiencing ICH or new FND. Sensitivity analyses excluding events attributable primarily to the CCM showed no change in the significance or magnitude of the association.
Overall, this study provides compelling evidence that CCM excision may worsen short-term disability scores and increase the risk of symptomatic ICH and new neurologic deficits. Contrary to prior conventional wisdom that selected symptomatic patients should undergo surgery, this study shows worsened outcomes in those who do so. The strengths of the study include the unbiased prospective populationbased dataset, detailed case assessment, predefined control group, and near complete follow-up (97%), as well as independent neuroimaging review and outcome assessment.
The study has some limitations. This is not a randomized trial, and there were no predetermined selection criteria for which patients had conservative vs surgical management. Therefore, systematic treatment selection bias cannot be excluded, as sicker patients (ICH, FND) may have been preferentially selected for microsurgical excision. Curiously, the patients progressing to primary outcome did so 1.5 years after treatment, suggesting other, as yet undetermined, confounding factors that contributed to progressive worsening in surgically treated patients. Also, the potential effect of multiple (i.e., genetically determined) CCMs on progressive worsening remains unclear from the data.
These considerations aside, surgical cavernoma excision cannot be routinely recommended, especially for patients with asymptomatic CCM, based on the risks documented in this study. These data provide ample justification for a randomized controlled trial evaluating patient management with or without surgical CCM excision. Similar concerns for arteriovenous malformations have led to a randomized controlled trial that recently confirmed the superiority of noninterventional management over invasive management for the prevention of death and symptomatic stroke for cases with nonhemorrhagic lesions. 5 The same may be true for patients with CCM.
